In this interview, Meriem Sefta from Owkin discusses her journey from academia to her role at Owkin, where she focuses on applying AI to digital pathology. She explains how Owkin's innovative approach leverages AI to analyze digital pathology slides and link molecular and morphological data for improved diagnostics and drug discovery. Sefta highlights Owkin's partnerships with hospitals to securely access real-world clinical data, which enhances their AI models. She also discusses their CE-marked products for colorectal and breast cancer, as well as the broader impact of AI on the future of pathology, drug development, and personalized medicine.